PL3601296T3 - Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwych - Google Patents
Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwychInfo
- Publication number
- PL3601296T3 PL3601296T3 PL18716193.0T PL18716193T PL3601296T3 PL 3601296 T3 PL3601296 T3 PL 3601296T3 PL 18716193 T PL18716193 T PL 18716193T PL 3601296 T3 PL3601296 T3 PL 3601296T3
- Authority
- PL
- Poland
- Prior art keywords
- cancers
- oxo
- inhibitors
- compounds
- treatment
- Prior art date
Links
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163781 | 2017-03-30 | ||
| US201762565281P | 2017-09-29 | 2017-09-29 | |
| EP17194084 | 2017-09-29 | ||
| ARP180100778A AR111200A1 (es) | 2017-03-30 | 2018-03-28 | Derivados de tiocarbamato como inhibidores de a2a y métodos para usar en el tratamiento de cánceres |
| PCT/EP2018/058301 WO2018178338A1 (en) | 2017-03-30 | 2018-03-30 | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3601296T3 true PL3601296T3 (pl) | 2022-10-10 |
Family
ID=61911575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18716193.0T PL3601296T3 (pl) | 2017-03-30 | 2018-03-30 | Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwych |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995101B2 (pl) |
| EP (2) | EP3601296B1 (pl) |
| JP (2) | JP7197558B2 (pl) |
| KR (2) | KR20240027885A (pl) |
| CN (3) | CN115991679A (pl) |
| AU (1) | AU2018246355B2 (pl) |
| BR (1) | BR112019020421A8 (pl) |
| CA (1) | CA3058260A1 (pl) |
| DK (1) | DK3601296T3 (pl) |
| ES (1) | ES2926158T3 (pl) |
| HR (1) | HRP20221039T1 (pl) |
| HU (1) | HUE059990T2 (pl) |
| IL (2) | IL300149A (pl) |
| LT (1) | LT3601296T (pl) |
| MX (2) | MX2019011743A (pl) |
| PL (1) | PL3601296T3 (pl) |
| RS (1) | RS63557B1 (pl) |
| SI (1) | SI3601296T1 (pl) |
| TW (1) | TWI836960B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202000431PA (en) | 2017-07-18 | 2020-02-27 | Nuvation Bio Inc | 1,8-naphthyridinone compounds and uses thereof |
| AU2018302179A1 (en) | 2017-07-18 | 2020-02-13 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| JP2022500496A (ja) * | 2018-09-11 | 2022-01-04 | アイテオ ベルギウム エスエー | Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
| CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
| ES2237576T3 (es) * | 2000-05-26 | 2005-08-01 | Schering Corporation | Antagonistas del receptor a2a de adenosina. |
| WO2004092171A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists |
| US7709492B2 (en) * | 2004-04-21 | 2010-05-04 | Schering Corporation | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
| WO2007140181A2 (en) | 2006-05-26 | 2007-12-06 | King Pharmaceuticals Research And Development, Inc. | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist |
| US7691869B2 (en) * | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| CA2694987A1 (en) | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Combinations for the treatment of b-cell proliferative disorders |
| WO2011112687A2 (en) | 2010-03-10 | 2011-09-15 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| CA2812378C (en) | 2010-09-24 | 2016-11-29 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
| WO2012055015A1 (en) | 2010-10-26 | 2012-05-03 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
| WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| CA3047600A1 (en) | 2017-01-20 | 2018-07-26 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
| WO2018178338A1 (en) | 2017-03-30 | 2018-10-04 | Iteos Therapeutics | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
| US20200316077A1 (en) | 2017-12-19 | 2020-10-08 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
| JP2022500496A (ja) | 2018-09-11 | 2022-01-04 | アイテオ ベルギウム エスエー | Ａ２ａ阻害剤としてのチオカルバメート誘導体、その医薬組成物、及び抗がん剤との組み合わせ |
| US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
| WO2020065036A1 (en) | 2018-09-27 | 2020-04-02 | Iteos Therapeutics S.A. | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
-
2018
- 2018-03-30 CN CN202211658370.5A patent/CN115991679A/zh active Pending
- 2018-03-30 CA CA3058260A patent/CA3058260A1/en active Pending
- 2018-03-30 HU HUE18716193A patent/HUE059990T2/hu unknown
- 2018-03-30 PL PL18716193.0T patent/PL3601296T3/pl unknown
- 2018-03-30 KR KR1020247005971A patent/KR20240027885A/ko not_active Application Discontinuation
- 2018-03-30 EP EP18716193.0A patent/EP3601296B1/en active Active
- 2018-03-30 CN CN201880034926.9A patent/CN110678472B/zh active Active
- 2018-03-30 IL IL300149A patent/IL300149A/en unknown
- 2018-03-30 BR BR112019020421A patent/BR112019020421A8/pt active Search and Examination
- 2018-03-30 TW TW112113401A patent/TWI836960B/zh active
- 2018-03-30 LT LTEPPCT/EP2018/058301T patent/LT3601296T/lt unknown
- 2018-03-30 AU AU2018246355A patent/AU2018246355B2/en active Active
- 2018-03-30 RS RS20220794A patent/RS63557B1/sr unknown
- 2018-03-30 HR HRP20221039TT patent/HRP20221039T1/hr unknown
- 2018-03-30 DK DK18716193.0T patent/DK3601296T3/da active
- 2018-03-30 KR KR1020197031322A patent/KR102640927B1/ko active IP Right Grant
- 2018-03-30 ES ES18716193T patent/ES2926158T3/es active Active
- 2018-03-30 SI SI201830747T patent/SI3601296T1/sl unknown
- 2018-03-30 JP JP2020503355A patent/JP7197558B2/ja active Active
- 2018-03-30 CN CN202211706953.0A patent/CN115873022A/zh active Pending
- 2018-03-30 MX MX2019011743A patent/MX2019011743A/es unknown
- 2018-03-30 EP EP22165965.9A patent/EP4112623A1/en active Pending
-
2019
- 2019-03-14 US US16/354,022 patent/US10995101B2/en active Active
- 2019-09-26 IL IL269710A patent/IL269710B2/en unknown
- 2019-09-30 MX MX2022005298A patent/MX2022005298A/es unknown
-
2020
- 2020-08-14 US US16/993,897 patent/US20210198281A1/en not_active Abandoned
-
2022
- 2022-09-21 US US17/949,595 patent/US20230159564A1/en active Pending
- 2022-12-15 JP JP2022199962A patent/JP2023027282A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249524A1 (zh) | 用於治療血載癌症的免疫檢查點抑制劑 | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL269710A (en) | 2-oxo-thiazole derivatives as A2A inhibitors and compounds for use in cancer therapy | |
| HK1256283A1 (zh) | 治療癌症有用的二氫咪唑並吡嗪酮衍生物 | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| IL258979B (en) | The use of pyrimidine and pyridine history in the treatment of cancer | |
| IL266198A (en) | Liposomal formulation for use in cancer treatment | |
| IL247586A0 (en) | Use of Aribolin and mtor inhibitors as a combined treatment for cancer | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| HK1250161B (zh) | 6-嗎啉基-2-吡唑基-9h-嘌呤衍生物及其作為pi3k抑制劑的用途 | |
| IL253933A0 (en) | History of pyrimidine use in the treatment of cancer | |
| EP3440052C0 (en) | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| PT3601296T (pt) | Derivados de 2-oxo-tiazóis como inibidores de a2a e compostos para uso no tratamento de cancros |